Structural and Activity Relationships of 6-Sulfonyl-8-Nitrobenzothiazinones as Antitubercular Agents

被引:25
作者
Fan, Dongguang [1 ]
Wang, Bin [2 ]
Stelitano, Giovanni [3 ]
Savkova, Karin [4 ]
Shi, Rui [1 ]
Huszar, Stanislav [4 ]
Han, Quanquan [1 ]
Mikusova, Katarina [4 ]
Chiarelli, Laurent R. [3 ]
Lu, Yu [2 ]
Qiao, Chunhua [1 ]
机构
[1] Soochow Univ, Coll Pharmaceut Sci, Suzhou 215123, Peoples R China
[2] Beijing Chest Hosp, Beijing TB & Thorac Tumor Res, Dept Pharmacol, Beijing Key Lab Drug Resistance TB Res, Beijing 101149, Peoples R China
[3] Univ Pavia, Dept Biol & Biotechnol, I-27100 Pavia, Italy
[4] Comenius Univ, Fac Nat Sci, Dept Biochem, Bratislava 84215, Slovakia
关键词
KILL MYCOBACTERIUM-TUBERCULOSIS; DRUG DEVELOPMENT; BENZOTHIAZINONES;
D O I
10.1021/acs.jmedchem.1c01049
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The benzothiazinone (BTZ) scaffold compound PBTZ169 kills Mycobacterium tuberculosis by inhibiting the essential flavoenzyme DprE1, consequently blocking the synthesis of the cell wall component arabinans. While extraordinarily potent against M. tuberculosis with a minimum inhibitory concentration (MIC) less than 0.2 ng/mL, its low aqueous solubility and bioavailability issues need to be addressed. Here, we designed and synthesized a series of 6-methanesulfonyl substituted BTZ analogues; further exploration introduced five-member aromatic heterocycles as linkers to attach an aryl group as the side chain. Our work led to the discovery of a number of BTZ derived compounds with potent antitubercular activity. The optimized compounds 6 and 38 exhibited MIC 47 and 30 nM, respectively. Compared to PBTZ169, both compounds displayed increased aqueous solubility and higher stability in human liver microsomes. This study suggested that an alternative side-chain modification strategy could be implemented to improve the druglike properties of the BTZ-based compounds.
引用
收藏
页码:14526 / 14539
页数:14
相关论文
共 19 条
[1]   Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review [J].
Angula, Klaudia T. ;
Legoabe, Lesetja J. ;
Beteck, Richard M. .
PHARMACEUTICALS, 2021, 14 (05)
[2]  
[Anonymous], 2020, Global Tuberculosis Report
[3]   Ubiquitin ligase TRAF2 attenuates the transcriptional activity of the core clock protein BMAL1 and affects the maximal Per1 mRNA level of the circadian clock in cells [J].
Chen, Suping ;
Yang, Jing ;
Yang, Lu ;
Zhang, Yang ;
Zhou, Liang ;
Liu, Qing ;
Duan, Chunyan ;
Mieres, Crystal A. ;
Zhou, Guanghai ;
Xu, Guoqiang .
FEBS JOURNAL, 2018, 285 (16) :2987-3001
[4]  
Ecole Polytechnique Federale de Lausanne, 2012, Patent No. [WO 2012/066518 A1, 2012066518, WO2012/066518A1]
[5]   Applications of Fluorine in Medicinal Chemistry [J].
Gillis, Eric P. ;
Eastman, Kyle J. ;
Hill, Matthew D. ;
Donnelly, David J. ;
Meanwell, Nicholas A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (21) :8315-8359
[6]   Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-D-ribofuranose 2′-Oxidase [J].
Karabanovich, Galina ;
Dusek, Jan ;
Savkova, Karin ;
Pavlis, Oto ;
Pavkova, Ivona ;
Korabecny, Jan ;
Kucera, Tomas ;
Vlckova, Hana Kocova ;
Huszar, Stanislav ;
Konyarikova, Zuzana ;
Konecna, Klara ;
Jand'ourek, Ondrej ;
Stolarikova, Jirina ;
Kordulakova, Jana ;
Vavrova, Katerina ;
Pavek, Petr ;
Klimesova, Vera ;
Hrabalek, Alexandr ;
Mikusova, Katarina ;
Roh, Jaroslav .
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (17) :8115-8139
[7]   Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents [J].
Liu, Lingfeng ;
Kong, Chengcheng ;
Fumagalli, Marco ;
Savkova, Karin ;
Xu, Yiwen ;
Huszar, Stanislav ;
Sammartino, Jose C. ;
Fan, Dongguang ;
Chiarelli, Laurent R. ;
Mikusova, Katarina ;
Sun, Zhaogang ;
Qiao, Chunhua .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 208
[8]   hERG optimizations of IMB1603, discovery of alternative benzothiazinones as new antitubercular agents [J].
Lv, Kai ;
Wang, Apeng ;
Tao, Zeyu ;
Fu, Lei ;
Liu, Hongtao ;
Wang, Bin ;
Ma, Chao ;
Wang, Hongjian ;
Ma, Xican ;
Han, Bing ;
Wang, Auyu ;
Zhang, Kai ;
Liu, Mingliang ;
Lu, Yu .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 179 :208-217
[9]   Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents [J].
Lv, Kai ;
You, Xuefu ;
Wang, Bin ;
Wei, Zengquan ;
Chai, Yun ;
Wang, Bo ;
Wang, Apeng ;
Huang, Guocheng ;
Liu, Mingliang ;
Lu, Yu .
ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (06) :636-641
[10]   Development of Macozinone for TB treatment: An Update [J].
Makarov, Vadim ;
Mikusova, Katarina .
APPLIED SCIENCES-BASEL, 2020, 10 (07)